Chemestmed is pleased to announce the signing of the Grant Agreement for the CALM6A project under the European Innovation Council (EIC) Pre-Accelerator programme.
Chemestmed was proud to participate in this year’s Swiss Biotech Day in Basel as part of the Estonian delegation and the Global Village initiative.
To advance precision mRNA delivery and stronger immune activation for colorectal cancer.
By combining our low-molecular-weight epitranscriptomic modulators with their targeted nanoparticle platform, we aim to unlock stronger immune activation and turn cold tumors hot.
The Chemestmed team has returned from three productive and inspiring days at BIO-Europe in Vienna, where our representatives, Sigrid Selberg and Mati Karelson engaged with a wide network of industry experts, innovators, and partners from across the biotech landscape.
Chemestmed was pleased to take part in a recent delegation of Estonian HealthTech innovators in London.
Chemestmed is proud to announce a new research collaboration with FutureNeuro, the Research Ireland Centre for Translational Brain Science, and the research team led by Dr. Gary Brennan at University College Dublin.
